MedTrace Logo

CDI-988 Safety Study in Healthy Participants

NCT05977140 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2025-08-17

No results posted yet for this study

Summary

The goal of this clinical trial is to learn about the safety and pharmacokinetics (PK, the amount of drug in the blood) of a new drug called CDI-988 in healthy volunteers.

The main questions it aims to answer are:

* Are there any side effects of the drug?
* What is the amount of drug that reaches the bloodstream? Participants will be assigned by chance to take either CDI-988 or placebo by mouth and have physical exams, electrocardiograms (ECGs), vital signs, and blood tests to look for any side effects.

Conditions

  • Healthy Volunteers

Interventions

DRUG

CDI-988

SARS-CoV-2 3CL protease inhibitor

DRUG

Placebo

matching placebo

Sponsors & Collaborators

  • Cocrystal Pharma Australia Pty Ltd.

    collaborator UNKNOWN

  • Beyond Drug Development Pty Ltd.

    collaborator UNKNOWN

  • Resolutum Global Pty Ltd.

    collaborator UNKNOWN

  • Scientia Clinical Research Pty Ltd

    collaborator UNKNOWN

  • Cocrystal Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Christopher Argent, MD · Scientia Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-27
Primary Completion
2025-05-23
Completion
2025-07-23

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05977140 on ClinicalTrials.gov